Novavax Inc. buy shadow
Start price
07.07.20
/
50%
€93.40
Target price
27.07.20
€110.00
Performance (%)
18.52%
End price
27.07.20
€110.70
Summary
This prediction ended on 27.07.20 with a price of €110.70. The prediction had a final performance of 18.52%. shadow has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novavax Inc. | -31.553% | -31.553% | 40.605% | -92.986% |
iShares Core DAX® | -3.935% | -2.628% | 10.013% | 11.951% |
iShares Nasdaq 100 | -3.608% | -9.283% | 20.668% | 35.711% |
iShares Nikkei 225® | -4.513% | -6.951% | 5.241% | 2.602% |
iShares S&P 500 | -2.607% | -4.402% | 20.177% | 37.820% |
According to shadow what are the pros and cons of Novavax Inc. for the foreseeable future?
Pros
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Good rating
Standard Investments for future growth
Capable Management
Top 10 in its market
Known brand
Future proof or reliable business model
Cons
Probably not worthwhile Investment
High valuation
Low dividend yield expected
negative Cash Flow expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Bad culture
Little innovation
Few uniques
Growths slower than the competition
Dependend from some customers or products
Sustainability is little important
high free float
Higher risks for its business
Significant cyclical dependencies
Comments by shadow for this prediction
In the thread Novavax Inc. diskutieren
Buy mit Kursziel 110,0
In the thread Trading Novavax Inc.
Buy beendet
Stopped prediction by shadow for Novavax Inc.
Novavax Inc.
Start price
Target price
Perf. (%)
€110.70
27.07.20
27.07.20
-
04.11.21
04.11.21
50.84%
05.11.21
05.11.21
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Probably not worthwhile Investment
High valuation